ArticleJTO clinical and research reports2026

Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].

Surbhi Singhal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.